Associated Genetic Biomarkers
XRCC6 Mutation serves as an inclusion eligibility criterion in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain XRCC6 Mutation as an inclusion criterion, 2 are phase 2 (2 open).
Trials with XRCC6 Mutation in the inclusion eligibility criteria most commonly target melanoma and urothelial carcinoma .
Nivolumab, olaparib, and talazoparib are the most frequent therapies in trials with XRCC6 Mutation as an inclusion criteria .
Significance of XRCC6 Mutation in Diseases
XRCC6 is altered in 4.44% of melanoma patients with XRCC6 Mutation present in 4.0% of all melanoma patients .
XRCC6 Mutation is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC6 Mutation and melanoma as inclusion criteria, 1 is phase 2 (1 open) .
Urothelial Carcinoma +
XRCC6 Mutation is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC6 Mutation and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.